- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12. | CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco's departure | 1 | Seeking Alpha | ||
| 17.12. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12. | Führungswechsel bei CNS Pharmaceuticals: Rami Levin wird neuer CEO | 7 | Investing.com Deutsch | ||
| 17.12. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces CEO Transition | 261 | ACCESS Newswire | Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company")... ► Artikel lesen | |
| 21.11. | CNS Pharmaceuticals: Aktionäre stimmen Kapitalerhöhung und Wahl des Verwaltungsrats zu | 2 | Investing.com Deutsch | ||
| 21.11. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.11. | CNS Pharmaceuticals reports Q3 results | 2 | Seeking Alpha | ||
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 17.11. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 369 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the... ► Artikel lesen | |
| 14.11. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology 30th Annual Meeting | 242 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments... ► Artikel lesen | |
| 03.09. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference | 346 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments... ► Artikel lesen | |
| 15.08. | CNS Pharmaceuticals reports Q2 results | 1 | Seeking Alpha | ||
| 15.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 488 | ACCESS Newswire | Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON... ► Artikel lesen | |
| 14.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech | 404 | ACCESS Newswire | - Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| 22.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference | 345 | ACCESS Newswire | - Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in... ► Artikel lesen | |
| 22.07. | XFRA BE50: AUSSETZUNG/SUSPENSION | 317 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCNS PHARM.INC.NEW... ► Artikel lesen | |
| 22.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 22.07.2025 | 1.068 | Xetra Newsboard | The following instruments on XETRA do have their first trading 22.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 22.07.2025
Aktien
1 NGGTCO000002 Guaranty Trust Holding... ► Artikel lesen | |
| 21.07. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.07.2025 | 433 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 21.07.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.07.2025ISIN NameCA7703631092 ROBERTO... ► Artikel lesen | |
| 21.07. | XFRA ISIN CHANGE | 467 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS18978H4092 CNS Pharmaceuticals Inc. 21.07.2025 US18978H5081 CNS Pharmaceuticals Inc. 22.07.2025 Tausch 12:1CA86218J2048 Storm... ► Artikel lesen | |
| 18.07. | CNS Pharmaceuticals announces 1-for-12 reverse stock split | 4 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,478 | +1,70 % | Sonntagsausblick: Curevac-Aktie vor spannender Handelswoche - Experten sind sich uneinig! | ||
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,970 | -1,63 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| PROTAGONIST THERAPEUTICS | 88,78 | -0,07 % | Protagonist Therapeutics: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 39,640 | -1,59 % | Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday | ||
| VERA THERAPEUTICS | 53,58 | -3,75 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| CELCUITY | 102,25 | -0,35 % | Celcuity Inc.: Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer | MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion... ► Artikel lesen | |
| IMMUNOVANT | 26,160 | -2,68 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,880 | -2,14 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,280 | -1,33 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 268,95 | -2,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 26,360 | -3,41 % | Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy | - In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,040 | -1,52 % | Dyne Therapeutics appoints Vikram Karnani to board of directors | ||
| ARCELLX | 65,71 | -0,44 % | Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset | ||
| CG ONCOLOGY | 39,840 | -0,75 % | CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,180 Euro und damit +0,82 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.